Nasdaq:US$36.56 (-0.93) | HKEX:HK$58.70 (+0.05) | AIM:£5.38 (-0.09)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors